Phase 3Active, not recruitingAge-related condition
ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)
ReNEW: A Phase 3, Double-Masked, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects Who Have Dry Age-Related Macular Degeneration (Dry AMD)
- Sponsor
- Stealth BioTherapeutics Inc. (Industry)
- Enrollment
- 313 enrolled
- Conditions
- Age Related Macular Degeneration (ARMD)
- Interventions
- Elamipretide; Placebo
- Ages
- adults, older adults
- Registry
- NCT06373731
Full record on ClinicalTrials.gov
From the registry
The goal of this clinical trial is to evaluate the efficacy, safety and pharmacokinetics of elamipretide in subjects with dry age-related macular degeneration (AMD). The main questions it aims to answer are: what is the rate of change in the macular area of photoreceptor loss in subjects who receive a daily dose of elamipretide compared with those who receive a look-alike substance that contains no active drug, and what is the safety and tolerability of elamipretide daily subcutaneous injections. Participants will receive either once daily subcutaneous doses of 40mg elamipretide or placebo and the two treatment groups will be compared.
Primary outcomes
- Week 48 Rate of change in the macular area of photoreceptor loss
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered